alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › disease-modifying-therapies

disease-modifying-therapies

6 studies tagged disease-modifying-therapies, dated 2019-04-25 to 2026-11-04. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Clinical genetics and genetic counseling in the era of disease-modifying therapies for dementia: lessons from Japan 2026-11-04
  2. Organizing healthcare delivery in the era of disease-modifying therapies for Alzheimer's Disease: an Italian RAND/UCLA consensus 2026-10-09
  3. [Anti-amyloid Antibody Drugs as Disease-Modifying Therapies for Alzheimer's Disease] 2024-09-01

Studies

6 studies carry this tag.

Date range

2019 to 2026

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 1
  • Brain and nerve = Shinkei kenkyu no shinpo 1
  • Expert opinion on investigational drugs 1
  • Expert review of neurotherapeutics 1
  • Journal of human genetics 1

6 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Clinical genetics and genetic counseling in the era of disease-modifying therapies for dementia: lessons from Japan

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of human genetics 2026-11-04 Treatments

    Recent advances in hereditary dementia research have clarified its molecular pathogenesis and clinical applications, with several advances already reaching implementation.

  2. Organizing healthcare delivery in the era of disease-modifying therapies for Alzheimer's Disease: an Italian RAND/UCLA consensus

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026-10-09 Treatments

    This consensus provides a pragmatic framework to support the reorganisation of AD care in Italy, ensuring that every patient is directed to the most appropriate level of care across a flexible regional network.

  3. [Anti-amyloid Antibody Drugs as Disease-Modifying Therapies for Alzheimer's Disease]

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Brain and nerve = Shinkei kenkyu no shinpo 2024-09-01 Treatments

    Alzheimer's disease (AD) is a common dementia disorder in the elderly individuals, accounting for approximately 60-70% of all dementia cases.

  4. Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2020-08-20 Treatments

    Empirical evidence suggests that a fair proportion of dementia cases are preventable, that some preventive actions can be taken immediately, and others may soon be implemented.

  5. Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Expert opinion on investigational drugs 2020-07-26 Drug development

    Alzheimer's disease (AD) is the main cause of dementia and represents a huge burden for patients, carers, and healthcare systems.

  6. Disease-modifying therapies for tauopathies: agents in the pipeline

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Expert review of neurotherapeutics 2019-04-25 Drug development

    Tauopathies are heterogeneous clinicopathological entities characterized by abnormal neuronal and/or glial inclusions of the microtubule-binding protein tau.

All topic tags with their study counts